Precision-Cut Lung Slices (PCLS): The ex vivo Frontier in Fibrosis Drug Discovery

Introduction: Why the Surge in "PCLS" Testing?

In fibrosis drug discovery, the demand for robust ex vivo models that bridge the translational gap between in vitro (cell culture) and in vivo (animal models) is accelerating rapidly. At the forefront of this shift within respiratory and pulmonary fibrosis research is the use of Precision-Cut Lung Slices (PCLS).

As regulatory agencies like the FDA and EMA increasingly promote alternative methods aligned with the 3Rs (Replacement, Reduction, Refinement) of animal welfare, PCLS—which retains full 3D organ architecture and multicellular interactions—has become an indispensable infrastructure for next-generation drug screening.

1. Principles and Core Advantages of PCLS

PCLS involves using a specialized tissue slicer (such as a vibratome) to cut living tissue (e.g., lung, liver) into uniform slices of a few hundred micrometers thick (typically 200–300 μm), which are then cultured in specialized media for days or even weeks.

Compared to Traditional in vitro (2D/3D Cultures)

When isolated fibroblasts or macrophages are plated in a standard petri dish, they lose their intricate Extracellular Matrix (ECM) microenvironment and the spatial relationships with airways, blood vessels, and immune cells. PCLS maintains this near-native in vivo microenvironment. Applying profibrotic stimuli like TGF-β to intact slices reproduces highly translatable pathophysiology that single-cell cultures cannot capture.

Compared to in vivo Animal Models (Applying the 3Rs)

Because dozens of slices can be generated from a single mouse lung (and hundreds from a single resected human lung lobe), it enables high-throughput concentration-response screening and cocktail testing from vastly fewer animals (Reduction). It also minimizes the pain and distress associated with prolonged in vivo dosing (Refinement), strongly aligning with ethical mandates.

2. Standard Protocol for Fibrosis Induction (Mouse Lung PCLS)

A typical workflow for inducing and evaluating fibrosis in murine PCLS is as follows:

Tissue Inflation via Agarose: Following euthanasia, the trachea is cannulated, and a low melting point agarose solution is instilled to inflate the lungs. The lungs are chilled, allowing the agarose to solidify, which prevents airway and alveolar collapse during slicing.
Precision Slicing: Using a vibratome, the lung lobes are cut into uniform slices (approx. 250–300 μm).
Washing & Acclimatization: The slices are incubated overnight to allow the agarose to dissolve out into the media and to let the cells equilibrate.
Induction of Fibrosis (e.g., TGF-β): The most common approach is supplementing the culture media with TGF-β1, Bleomycin, or a pro-fibrotic cocktail (e.g., TGF-β1 + PDGF-BB + TNF-α) spanning anywhere from 48 hours up to 7 days depending on the protocol.
Compound Dosing: Depending on the study design, test articles can be applied prophylactically (co-administered with the inducer) or therapeutically (days after induction).

[!NOTE] Human PCLS Advanced CROs are generating PCLS from non-diseased human lung tissue (derived from tumor resections) or from explanted IPF lungs representing end-stage disease. Testing compounds in human PCLS offers arguably the highest predictive value for clinical trial success currently available in preclinical pipelines.

3. Major Evaluation Endpoints (Readouts)

Given its robust, multicellular nature, PCLS affords highly multifaceted analyses.

① Biochemical and Molecular Readouts

Gene Expression (RT-qPCR): Rapid quantification of core fibrotic genes like Col1a1, Acta2 (α-SMA), and Fn1 (Fibronectin).
Secreted Proteins: Utilizing ELISAs or multiplex assays to measure pro-collagen peptides (PINP, PIIINP) and inflammatory cytokines released directly into the culture supernatant.
Viability Assays (WST-1, ATP assays): Crucial for distinguishing true anti-fibrotic effects from mere compound cytotoxicity.

② Histological and Morphological Readouts

Immunofluorescence / IHC: Staining for α-SMA and collagens allows image analysis (e.g., ImageJ morphometry) to quantify not only how much fibrosis occurred, but precisely where it localized relative to airways and vessels.
Airway Reactivity: Using video microscopy, the dynamic constriction of bronchioles in response to methacholine can be natively recorded and quantified, allowing assessment of functional tissue stiffness.

③ Cutting Edge: Biomechanical Assessment

Advanced setups now incorporate direct stiffness measurements of the slices using micro-indentation techniques or complex confocal elastography. Since "tissue stiffening" is the definitive functional consequence of fibrosis, measuring it directly provides high-value pharmacological data.

4. Current Limitations and Future Horizons

Despite its massive utility, PCLS is not without challenges.

Limited Lifespan: Standard culture viability declines after 5-7 days. While proprietary prolonged culture methods exist, the risk of central core necrosis or cellular dedifferentiation increases over time.
Lack of Circulating Immune Supply: Initial washing removes blood, and the slice cannot recruit "new" circulating immune cells (monocytes/neutrophils) from bone marrow in response to injury.

To solve these issues, the frontier is shifting toward Microphysiological Systems (MPS) & Organ-on-a-chip integrations. Researchers are beginning to house PCLS within specialized microfluidic chambers where perfusing media (pseudo-blood) provides shear stress and allows the continuous introduction of exogenous immune cells, creating a truly living, dynamic biological engine.

Summary

The PCLS (ex vivo) model operates as the ultimate "Goldilocks" platform—offering the speed and throughput of cell culture combined with the complex, multi-cellular, and architectural fidelity of an animal model. As the pharmaceutical industry pivots heavily toward human-relevant, 3Rs-compliant testing, PCLS is solidifying its position as the critical Go/No-Go gatekeeper between in vitro hit identification and costly in vivo validation.